TOKYO -- Until just several years ago, pharmaceutical manufacturer Daiichi Sankyo was one of the most unpopular public companies among investors in Japan, rocked by an internal feud and reeling from a disastrous acquisition in India. But it has roared back and is now one of the country's most valuable corporations.
With its market capitalization hitting 8.2 trillion yen ($78.9 billion) in late November -- the highest since the company's creation through a merger between two Japanese drugmakers in 2005 -- it is now ahead of Takeda Pharmaceutical, the sector's revenue leader in Japan, and competes with Chugai Pharmaceutical, a unit of Switzerland's Roche, for the title of the most valuable such corporation in Japan.
